Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Total Non-Current Liabilities (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Total Non-Current Liabilities for 16 consecutive years, with $46.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 3.91% to $46.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $46.1 million, a 3.91% decrease, with the full-year FY2025 number at $46.1 million, down 3.91% from a year prior.
  • Total Non-Current Liabilities was $46.1 million for Q4 2025 at Anika Therapeutics, up from $41.9 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $84.0 million in Q1 2021 to a low of $39.3 million in Q2 2025.
  • A 5-year average of $56.7 million and a median of $56.5 million in 2022 define the central range for Total Non-Current Liabilities.
  • Biggest YoY gain for Total Non-Current Liabilities was 29.32% in 2021; the steepest drop was 51.97% in 2021.
  • Anika Therapeutics' Total Non-Current Liabilities stood at $59.2 million in 2021, then rose by 6.72% to $63.2 million in 2022, then fell by 8.24% to $58.0 million in 2023, then dropped by 17.22% to $48.0 million in 2024, then dropped by 3.91% to $46.1 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Total Non-Current Liabilities are $46.1 million (Q4 2025), $41.9 million (Q3 2025), and $39.3 million (Q2 2025).